Bifidobacterium breve capable of relieving rheumatoid arthritis and application thereof

Patent metadata

Field	Value
Publication number	US-12285448-B2
Application number	US-202217696959-A
Country	US
Kind code	B2
Filing date	Mar 17, 2022
Priority date	Sep 3, 2020
Publication date	Apr 29, 2025
Grant date	Apr 29, 2025

Abstract

Described is a B. breve strain for relieving rheumatoid arthritis and application thereof, belonging to the technical field of microorganisms. Described is a B. breve strain CCFM1078 possessing the effect of relieving rheumatoid arthritis, and shown to: promote secretion of anti-inflammatory factor IL-10 from RAW264.7 cells; reduce joint thickness, clinical score, and incidence of rats with rheumatoid arthritis; decrease levels of the pro-inflammatory cytokines TNFα and IL-1β in the serum of rats with rheumatoid arthritis; regulate the content of short-chain fatty acids in the feces of rats with rheumatoid arthritis; decrease the proportion of Th17 cells in the mesenteric lymph nodes of rats with rheumatoid arthritis; and reduce secretion of pro-inflammatory factor IL-6 from synovial cells.

First claim

What is claimed is:

1. A drug, comprising:
freeze-dried Bifidobacterium breve ( B. breve ) CCFM1078; and
a protective agent,
wherein the B. breve is preserved at the Guangdong Microbial Culture Collection Center on May 6, 2020, with the preservation number GDMCC No: 61011,
wherein the B. breve comprises an 16S rDNA sequence set forth in SEQ ID NO: 1 and a genome of 2.36 Mb, and a G+C content of 58.90%, and
wherein the protective agent is selected from one or more of skim milk, trehalose, and sucrose.

2. The drug of claim 1 , wherein the viable count of the B. breve in the drug is not less than 1×10 5 CFU/mL or 1×10 5 CFU/g.

3. A process for preparing the drug of claim 1 , which comprises:
inoculating an MRS liquid medium with the B. breve;
culturing the bacteria anaerobically at 30° C. to 37° C;
collecting bacterial cells;
washing the bacterial cells with sterile normal saline;
resuspending the bacterial cells with a freeze-drying protectant which comprises trehalose to a concentration ≥5×10 10 CFU/mL to obtain a resuspension; and
freeze-drying the resuspension by vacuum freezing to obtain a freeze-dried B. breve powder.

4. The drug of claim 2 , further comprising a drug carrier and/or pharmaceutical excipients.

5. The drug of claim 1 , wherein upon administration of a pharmaceutically effective amount of the drug to a subject in need thereof by ingestion, the drug: (a) promotes secretion of IL-10 in the subject, (b) decreases serum levels of TNFα and IL-1β in the subject, (c) decreases a proportion of Th17 cells in feces of the subject, (d) reduced secretion of IL-6 from synovial cells of the subject, and/or (e) reduced joint thickness, clinical score, and incidence of rheumatoid arthritis in the subject, wherein the subject has or has been diagnosed with rheumatoid arthritis.

6. The drug of claim 1 , further comprising one or more of: (i) dairy, (ii) beans, (iii) meat, and/or (iv) fruit.

Assignees

• Univ Jiangnan

Inventors

• Yang Bo
• Chen Wei
• Fan Zhexin
• Zhai Qixiao
• Wang Gang
• Lu Wenwei
• Cui Shumao
• Zhao Jianxin
• Zhang Hao

Classifications

• A23V2400/519

  Breve · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title

• A23L2/52

  Adding ingredients (adding preservatives A23B70/10) · CPC title

• A61P19/02 Primary

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A23L33/40

  Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula · CPC title